Leveraging induced cell states for cancer therapy: The case for dynamic synthetic lethality.

Therapy can drive persisting cancer cells into a heightened, time-limited metabolic dependency state that is linked to metabolic differences between cancer and normal cells.

• Why it matters: Treatment creates selection pressure that accentuates metabolic disparities, leaving a vulnerable window in which persister cells rely on specific metabolic functions.
• What they did: The work proposes exploiting the therapy-induced interval using metabolic modifiers to target the heightened dependencies of persisting cells.
• The result: Using metabolic modifiers during this time-limited dependency is argued to enable persister cell death and improve cancer outcomes.

AI summary of the abstract · may contain errors · not medical advice · read the paper.